Pacira Pharmaceuticals reported $116.79M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acelrx Pharmaceuticals ACRX:US USD -62000 244K
Aerie Pharmaceuticals AERI:US USD 29.2M 370K
Amerisourcebergen ABC:US USD 1.99B 57.43M
Astellas Pharma 4503:JP JPY 317.61B 24.69B
Bristol Myers Squibb BMY:US USD 8.86B 345M
Cara Therapeutics CARA:US USD 7.76M 15.24M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Horizon Pharma HZNP:US USD 691.23M 45.03M
Johnson & Johnson JNJ:US USD 15.98B 134M
Lannett LCI:US USD 12.6M 4.74M
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Perrigo Ordinary Shares PRGO:US USD 362.9M 9.2M
Pfizer PFE:US USD 16.55B 2.52B
Revance Therapeutics RVNC:US USD 18.28M 566K
Teva Pharmaceutical TEVA:IT USD 1.71B 118M
Xeris Pharmaceuticals Inc XERS:US USD 24.46M 3.97M
Zoetis ZTS:US USD 1.4B 36M